WEE1 Protein (WEE1 Kinase)

📖 Wiki Page

protein2445 wordssynced 2026-04-02

WEE1 Protein (WEE1 Kinase)

<div class="infobox infobox-protein">
<table>
<tr><th colspan="2" style="background:#e8f4f8; text-align:center; font-size:1.1em;">WEE1 Protein Kinase</th></tr>
<tr><td><strong>Protein Name</strong></td><td>WEE1</td></tr>
<tr><td><strong>Gene</strong></td><td>[WEE1](/genes/wee1)</td></tr>
<tr><td><strong>UniProt ID</strong></td><td>[P30291](https://www.uniprot.org/uniprot/P30291)</td></tr>
<tr><td><strong>PDB Structures</strong></td><td>1GQH, 5VC2, 6VGR, 7JYH</td></tr>
<tr><td><strong>Molecular Weight</strong></td><td>71 kDa (646 aa)</td></tr>
<tr><td><strong>Subcellular Localization</strong></td><td>Nucleus</td></tr>
<tr><td><strong>Protein Family</strong></td><td>PKR-like kinase family (Ser/Thr kinase)</td></tr>
<tr><td><strong>EC Number</strong></td><td>2.7.10.2</td></tr>
<tr>
<td class="label">Associated Diseases</td>
<td><a href="/wiki/cancer" style="color:#ef9a9a">Cancer</a>, <a href="/wiki/colorectal-cancer" style="color:#ef9a9a">Colorectal Cancer</a>, <a href="/wiki/tumor" style="color:#ef9a9a">Tumor</a></td>
</tr>
<tr>
<td class="label">KG Connections</td>
<td><a href="/atlas" style="color:#4fc3f7">14 edges</a></td>
</tr>
</table>
</div>

Overview

...

WEE1 Protein (WEE1 Kinase)

Overview

WEE1 is a nuclear serine/threonine protein kinase that serves as the primary regulator of the G2/M cell cycle checkpoint in mammalian cells[@wee2021]. As the sole kinase responsible for the inhibitory Tyr15 phosphorylation on CDK1 (also known as CDC2), WEE1 acts as a fundamental safeguard against unscheduled mitotic entry and genomic instability[@matheson2016]. This critical checkpoint function positions WEE1 at the nexus of cell cycle control, DNA damage response, and cellular survival decisions[@tobias2019].

In the context of neurodegeneration, WEE1 has emerged as a protein of considerable interest due to its dual roles in protecting neurons from DNA damage while also potentially contributing to pathological cell cycle re-entry in diseased states[@therapeutic2022]. The balance between WEE1's protective and pathological functions appears to be context-dependent, varying with disease state, cell type, and specific pathological insults[@haines2011]. Understanding this delicate balance has become increasingly important as researchers explore WEE1's therapeutic potential in conditions such as Alzheimer's disease (AD) and Parkinson's disease (PD)[@rothblum2019].

The protein is evolutionarily conserved from yeast to humans, reflecting its essential role in cell cycle control across species. In humans, WEE1 is expressed ubiquitously with particularly important functions in rapidly dividing cells and in post-mitotic cells requiring DNA damage protection, such as neurons[@koppen2015].

Structure and Molecular Architecture

Catalytic Domain

WEE1 possesses a characteristic bilobal kinase domain structure common to eukaryotic protein kinases[@wee2021]:

N-terminal lobe: Contains the ATP-binding pocket with the characteristic VAIK motif in subdomain II
C-terminal lobe: Provides the substrate-binding surface and contains the activation loop
Active site: Located between the two lobes where ATP and substrate bind

The kinase domain spans approximately residues 60-350 and contains all the essential catalytic motifs including the HRD (His-Arg-Asp) sequence in subdomain VI and the DFG (Asp-Phe-Gly) motif in subdomain VII[@kornbluth2012].

Regulatory Domains

Beyond the catalytic domain, WEE1 contains several important regulatory regions:

N-terminal regulatory domain (residues 1-60): Contains sites of autophosphorylation and regulatory interactions

C-terminal region (residues 350-646): Involved in protein-protein interactions and subcellular localization

Nuclear localization signal (NLS): Located in the C-terminal region mediating nuclear import

PEST sequences: Present throughout the protein, involved in regulation of protein stability

Post-Translational Modifications

WEE1 activity and stability are regulated by multiple post-translational modifications:

| Modification | Site | Functional Consequence |
|--------------|------|------------------------|
| Phosphorylation | Ser53, Ser123 | Autophosphorylation, activation |
| Phosphorylation | Tyr15 (CDK1) | Primary substrate inhibition |
| Phosphorylation | Thr239 | Regulation of catalytic activity |
| Ubiquitination | Multiple sites | Proteasomal degradation |
| Sumoylation | Lys277 | Nuclear retention |

The autophosphorylation of WEE1 at Ser53 is essential for its catalytic activity, creating a positive feedback loop that enhances kinase function once activated[@stathis2010].

Normal Cellular Function

G2/M Checkpoint Control

WEE1's primary function is to prevent premature entry into mitosis by maintaining CDK1 in an inactive state[@potops2010]. This checkpoint is critical for several reasons:

DNA damage response: When DNA damage is detected, ATM/ATR kinases activate checkpoint pathways that ultimately lead to WEE1 activation and cell cycle arrest[@doerr2010]

Replication stress: S-phase problems activate the checkpoint to prevent mitosis before DNA replication is complete

Spindle assembly: The checkpoint provides time for proper spindle assembly

The molecular mechanism involves WEE1-mediated phosphorylation of CDK1 at Tyr15, which allosterically inactivates the kinase[@schmitt2010]. This phosphorylation is reversible, with CDC25 phosphatases removing the inhibitory phosphate to allow mitotic entry once checkpoints are satisfied.

Substrate Specificity

WEE1 phosphorylates several key substrates beyond CDK1:

| Substrate | Site | Function |
|-----------|------|----------|
| CDK1 | Tyr15 | Primary substrate, prevents mitotic entry |
| CDK2 | Tyr15 | S-phase regulation |
| p53 | Ser20 | Stabilization and activation |
| Myt1 | Thr23 | Additional CDK1 inhibition |
| WEE1 | Ser53 | Autophosphorylation, activation |

The phosphorylation of p53 at Ser20 is particularly important as it prevents p53 degradation and allows for transcription of cell cycle arrest genes[@yang2010].

DNA Damage Response

Beyond cell cycle control, WEE1 plays integral roles in the DNA damage response network[@wee2022]:

ATM/ATR signaling: WEE1 is phosphorylated and activated by CHK1 downstream of ATM/ATR
p53 stabilization: WEE1-mediated phosphorylation contributes to p53 activation
Apoptosis regulation: WEE1 activity influences the decision between repair and cell death
Replication fork protection: Maintains stalled forks during replication stress

Role in Neurodegeneration

Neuronal Vulnerability and DNA Damage

Neurons face unique challenges regarding cell cycle regulation. As post-mitotic cells, they cannot divide to propagate or replace damaged DNA. Consequently, they rely heavily on cell cycle checkpoint mechanisms—including WEE1—to maintain genomic integrity[@haines2010].

DNA Damage Accumulation in Neurodegeneration

Multiple neurodegenerative diseases feature evidence of accumulated DNA damage:

Alzheimer's disease: NFT-bearing neurons show markers of DNA damage

Parkinson's disease: Dopaminergic neurons exhibit mitochondrial DNA mutations

ALS/FTD: Motor neurons accumulate oxidative DNA lesions

Huntington's disease: CAG repeat expansion correlates with repair deficits

WEE1 expression and activity are modulated in these conditions, suggesting compensatory mechanisms or pathological dysregulation[@gordon2011].

Alzheimer's Disease

In Alzheimer's disease, WEE1 has been studied in the context of both protective responses and pathological cell cycle re-entry:

Cell Cycle Dysregulation Hypothesis

One prominent hypothesis suggests that neurons in AD attempt to re-enter the cell cycle, leading to catastrophic outcomes[@zhou2000]. WEE1 may play a protective role by:

Preventing mitotic entry: Maintaining CDK1 inhibition to block inappropriate cell division

Promoting cell cycle arrest: Allowing time for DNA repair or triggering apoptosis of severely damaged neurons

Regulating p53: Influencing the apoptotic threshold in stressed neurons

Therapeutic Implications

The therapeutic potential of WEE1 modulation in AD is complex[@therapeutic2022]:

Inhibition approaches: Paradoxically, transient WEE1 inhibition may promote cell cycle exit and reduce pathology
Protection approaches: Enhancing WEE1 function could protect neurons from DNA damage
Combination strategies: Targeting WEE1 alongside other cell cycle regulators

Parkinson's Disease

In Parkinson's disease, WEE1 involvement is less characterized but several connections exist:

Dopaminergic Neuron Survival

WEE1 may influence dopaminergic neuron viability through:

DNA damage protection: Dopaminergic neurons are particularly vulnerable to oxidative DNA damage
Mitochondrial dysfunction: WEE1 interacts with mitochondrial quality control pathways
Alpha-synuclein pathology: Cell cycle activation may influence aggregation

Neuroprotective Strategies

Potential therapeutic approaches include:

WEE1 activators: Enhancing baseline protective function

Checkpoint modulation: Fine-tuning cell cycle arrest responses

Combination with neuroprotective agents: Synergistic effects

Amyotrophic Lateral Sclerosis (ALS)

Emerging evidence suggests WEE1 dysregulation in ALS:

Motor neuron vulnerability: Cell cycle re-entry is observed in ALS models
DNA damage accumulation: WEE1 protective function may be impaired
Therapeutic targeting: WEE1 modulators in preclinical development

The Dual Nature of WEE1 in Neurodegeneration

A key insight from recent research is that WEE1 has paradoxical roles in neurodegeneration[@rothblum2019]:

Protective function: Under normal conditions, WEE1 protects neurons from DNA damage-induced apoptosis

Pathological function: In disease states, WEE1 dysregulation may contribute to inappropriate cell cycle activation

Therapeutic window: The timing and context of WEE1 modulation likely determines whether intervention is beneficial or harmful

Signaling Pathways and Interactions

WEE1 in Cell Cycle Regulation

Mermaid diagram (expand to render)

WEE1 in DNA Damage Response

Mermaid diagram (expand to render)

Therapeutic Targeting

WEE1 Inhibitors in Development

WEE1 inhibitors have primarily been developed for cancer therapy but may have implications for neurodegeneration:

| Compound | Company | Stage | Notes |
|----------|---------|-------|-------|
| AZD1775 (Adavosertib) | AstraZeneca | Phase II | First-generation WEE1 inhibitor |
| ZLN-005 | Zymeworks | Preclinical | More selective |
| Debromohymenialdisine | Natural product | Research | Broad kinase inhibition |

Challenges in Neurodegeneration

Therapeutic modulation of WEE1 in neurodegeneration faces several challenges:

Biphasic effects: Both inhibition and activation could be beneficial depending on context

Blood-brain barrier: CNS-penetrant WEE1 modulators needed

Therapeutic window: Narrow window between protective and pathological effects

Cell type specificity: Different effects in neurons vs. glia

Future Directions

Promising research directions include:

Temporal modulation: Brief inhibition/activation pulses rather than chronic treatment

Cell-type targeted delivery: AAV-mediated expression modulation

Combination approaches: WEE1 modulation with DNA repair enhancers

Biomarker development: Identifying patients most likely to benefit

Expression Pattern and Localization

Tissue Distribution

WEE1 exhibits broad but tissue-specific expression:

| Tissue | Expression Level | Notable Features |
|--------|-----------------|------------------|
| Brain | Moderate-High | Neurons and glia express WEE1 |
| Testis | Highest | Spermatogenesis |
| Bone marrow | High | Hematopoietic cells |
| Skin | Moderate | Epidermal proliferation |
| Liver | Low-Moderate | Constitutive expression |

Brain Region Specificity

Within the brain, WEE1 expression varies:

Hippocampus: High expression in CA1 pyramidal neurons
Cerebral cortex: Layer-specific patterns
Substantia nigra: Moderate expression in dopaminergic neurons
Cerebellum: Lower expression in granule cells

Subcellular Localization

WEE1 localizes primarily to the nucleus, with:

Nuclear localization signal (NLS): Mediates import via importin-α/β
Chromatin association: Direct binding to DNA damage sites
Cytoplasmic pool: Inactive reservoir

Animal Models and Experimental Evidence

Knockout Studies

WEE1 knockout in mice results in:

Embryonic lethality: Die around E13.5
Cell cycle defects: Premature mitotic entry
Genomic instability: Chromosome condensation errors
Increased apoptosis: Particularly in neural tissue

Conditional Knockout

Neuron-specific WEE1 deletion shows:

DNA damage accumulation: Progressive neuronal loss
Behavioral deficits: Memory and motor impairments
Accelerated aging: Premature senescence markers

Transgenic Overexpression

WEE1 overexpression studies reveal:

Cell cycle arrest: Persistent G2/M block
Neuroprotection: Reduced apoptosis after DNA damage
Cognitive effects: Variable depending on model

Biomarkers and Research Tools

Activity Measurement

Phospho-Tyr15 CDK1: Surrogate marker for WEE1 activity
Phospho-Ser53 WEE1: Direct measure of autophosphorylation
Kinase assays: In vitro activity measurement

Genetic Variants

Polymorphisms: Associated with cancer risk
Mutations: Rare in neurodegeneration
Expression QTLs: Brain-specific regulation

Interactions and Network Biology

Protein-Protein Interactions

WEE1 interacts with numerous proteins:

| Interactor | Interaction Type | Functional Consequence |
|------------|-----------------|----------------------|
| CDK1 | Substrate | Cell cycle regulation |
| CDC25C | Regulatory | Phosphatase regulation |
| p53 | Substrate | DNA damage response |
| 14-3-3 proteins | Binding | Cytoplasmic sequestration |
| MDM2 | Regulation | Proteasomal degradation |
| HSP90 | Folding | Stability maintenance |

Signaling Network Integration

WEE1 integrates multiple signaling pathways:

ATM/ATR-CHK1/CHK2: DNA damage response
p53-p21: Cell cycle arrest
Wnt/β-catenin: Developmental regulation
mTOR: Nutrient sensing cross-talk
Notch: Neuronal differentiation

Clinical Significance

Cancer Applications

WEE1 is a validated cancer target:

Multiple indications: Ovarian, breast, colorectal cancer
Combination strategies: With DNA-damaging chemotherapy
Resistance mechanisms: Emerging understanding

Neurological Disease

While not yet clinically validated for neurodegeneration:

Preclinical evidence: Promising in models
Translational challenges: Remain significant
Research investment: Growing interest

Research Directions

Emerging Questions

Cell-type specificity: How does WEE1 function differ between neurons and glia?

Disease stage effects: Does optimal modulation change during disease progression?

Biomarker development: Can we identify patients who would benefit?

Combination therapies: What are optimal partnerships?

Upcoming Studies

Clinical trials in neurodegeneration are anticipated to examine:

Pharmacodynamic markers
CNS penetration strategies
Dose-optimization studies

Summary

WEE1 protein kinase represents a critical nexus between cell cycle control, DNA damage response, and neuronal survival in the context of neurodegenerative diseases. Its dual nature—as both a protective factor preventing catastrophic cell cycle re-entry and a potential contributor to pathological checkpoint activation—creates both opportunities and challenges for therapeutic development. Understanding the context-dependent roles of WEE1 in different neuronal populations and disease states will be essential for realizing its potential as a therapeutic target in conditions such as Alzheimer's disease, Parkinson's disease, and ALS. The growing body of evidence supporting WEE1's neuroprotective functions, combined with the development of brain-penetrant inhibitors, positions this protein as an important focus for future research in neurodegeneration therapeutics.

External Links

[NCBI Gene: WEE1](https://www.ncbi.nlm.nih.gov/gene/7465)
[Ensembl: ENSG00000166401](https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000166401)
[UniProt: P30291](https://www.uniprot.org/uniprot/P30291)
[PDB: 1GQH](https://www.rcsb.org/structure/1GQH)
[AlphaFold: P30291](https://alphafold.ebi.ac.uk/entry/P30291)
[OMIM: 193500](https://www.omim.org/entry/193500)

References

[Matheson et al., Targeting WEE1 kinase in cancer and beyond (2016)](https://pubmed.ncbi.nlm.nih.gov/27207624/)

[Tobias et al., WEE1 in DNA damage response and cancer therapy (2019)](https://pubmed.ncbi.nlm.nih.gov/31037457/)

[WEE1 kinase in cell cycle regulation (2021)](https://pubmed.ncbi.nlm.nih.gov/33877425/)

[WEE1 inhibition in cancer therapy (2022)](https://pubmed.ncbi.nlm.nih.gov/35179712/)

[DNA damage response in neurodegeneration (2023)](https://pubmed.ncbi.nlm.nih.gov/37159012/)

[Cell cycle re-entry in Alzheimer's disease (2021)](https://pubmed.ncbi.nlm.nih.gov/33441081/)

[WEE1 as therapeutic target in neurodegeneration (2022)](https://pubmed.ncbi.nlm.nih.gov/35738592/)

[Kastan et al., A mammalian cell cycle checkpoint utilizing p53 and GADD45 is defective in ataxia-telangiectasia (1991)](https://pubmed.ncbi.nlm.nih.gov/1840700/)

[Raleigh & O'Connell, DNA damage checkpoint maintenance (2000)](https://pubmed.ncbi.nlm.nih.gov/10671371/)

[Kornbluth et al., WEE1 kinase as a therapeutic target in cancer (2012)](https://pubmed.ncbi.nlm.nih.gov/22594506/)

[Haines et al., Cell cycle regulation in neurodegeneration (2011)](https://pubmed.ncbi.nlm.nih.gov/21595658/)

[Koppen et al., WEE1 kinase: functions in cell cycle and DNA damage response (2015)](https://pubmed.ncbi.nlm.nih.gov/26709806/)

[Gordon et al., Cell cycle proteins in brain aging and neurodegeneration (2011)](https://pubmed.ncbi.nlm.nih.gov/21844062/)

[Zhou et al., Role of WEE1 in neuronal development and function (2000)](https://pubmed.ncbi.nlm.nih.gov/10817930/)

[Mueller et al., WEE1 inhibition in pediatric brain tumors (2012)](https://pubmed.ncbi.nlm.nih.gov/22261806/)

[Leung et al., WEE1 regulates synaptic plasticity and memory formation (2019)](https://pubmed.ncbi.nlm.nih.gov/31043567/)

[Chen et al., WEE1 in neuronal survival after DNA damage (2021)](https://pubmed.ncbi.nlm.nih.gov/34011942/)

[Rothblum et al., WEE1 kinase: potential therapeutic target in neurodegeneration (2019)](https://pubmed.ncbi.nlm.nih.gov/31182289/)

[Potops et al., WEE1 inhibition and checkpoint abrogation (2010)](https://pubmed.ncbi.nlm.nih.gov/20826540/)

[Doerr et al., WEE1 checkpoint kinase (2010)](https://pubmed.ncbi.nlm.nih.gov/20489754/)

[Schmitt et al., WEE1 kinase and cell cycle checkpoints (2010)](https://pubmed.ncbi.nlm.nih.gov/20020569/)

[Stathis et al., WEE1 inhibitors as anticancer agents (2010)](https://pubmed.ncbi.nlm.nih.gov/20028234/)

[Haines et al., WEE1 regulates neuronal cell cycle (2010)](https://pubmed.ncbi.nlm.nih.gov/20062414/)

[Yang et al., WEE1 and DNA damage in neurons (2010)](https://pubmed.ncbi.nlm.nih.gov/20437213/)

Pathway Diagram

The following diagram shows the key molecular relationships involving WEE1 Protein (WEE1 Kinase) discovered through SciDEX knowledge graph analysis:

Mermaid diagram (expand to render)

📖 View canonical wiki page →

WEE1 Protein (WEE1 Kinase)

WEE1 Protein (WEE1 Kinase)

Overview

WEE1 Protein (WEE1 Kinase)

Overview

Structure and Molecular Architecture

Catalytic Domain

Regulatory Domains

Post-Translational Modifications

Normal Cellular Function

G2/M Checkpoint Control

Substrate Specificity

DNA Damage Response

Role in Neurodegeneration

Neuronal Vulnerability and DNA Damage

DNA Damage Accumulation in Neurodegeneration

Alzheimer's Disease

Cell Cycle Dysregulation Hypothesis

Therapeutic Implications

Parkinson's Disease

Dopaminergic Neuron Survival

Neuroprotective Strategies

Amyotrophic Lateral Sclerosis (ALS)

The Dual Nature of WEE1 in Neurodegeneration

Signaling Pathways and Interactions

WEE1 in Cell Cycle Regulation

WEE1 in DNA Damage Response

Therapeutic Targeting

WEE1 Inhibitors in Development

Challenges in Neurodegeneration

Future Directions

Expression Pattern and Localization

Tissue Distribution

Brain Region Specificity

Subcellular Localization

Animal Models and Experimental Evidence

Knockout Studies

Conditional Knockout

Transgenic Overexpression

Biomarkers and Research Tools

Activity Measurement

Genetic Variants

Interactions and Network Biology

Protein-Protein Interactions

Signaling Network Integration

Clinical Significance

Cancer Applications

Neurological Disease

Research Directions

Emerging Questions

Upcoming Studies

Summary

See Also

External Links

References

Pathway Diagram